South Africa’s temporary halt on giving the US-developed Johnson & Johnson coronavirus vaccine as part of a mass clinical trial did not stop negotiations for a huge supply contract with local licensed producer Aspen Pharmacare — throwing a lifeline to its unused $210-million plant on the Indian Ocean coast.